Wellgistics Health Raises Capital Into Late 2026, Implements 1.3M Share Lock-Up Pre-DelivMeds AI
WGRX•Wellgistics Health’s mid-year outlook highlights a capital raise funding operations into late 2026, a lock-up limiting tradable shares to ~1.3 million and warrants extending funding through 2029. It plans to close the DelivMeds AI deal by Q3 2026 to expand its PharmacyChain™ blockchain, deploy medical drones and launch the Health Lives Here app.
1. Capital Raise and Debt Restructuring
The recent financing provided capital into late 2026 and restructuring of debt prevents issuing new shares until seven months after the transaction or thirty days after resale registration effectiveness. This condition stabilizes equity supply while aligning funding with strategic milestones.
2. Share Lock-Up and Warrants
A lock-up agreement limits tradable common shares to approximately 1.3 million, reducing immediate share float and potential selling pressure. Embedded warrants from the financing extend the company’s funding runway through 2029 upon exercise.
3. DelivMeds AI Transaction and Key Components
Wellgistics targets closing the DelivMeds AI transaction by the third quarter of 2026 to integrate its EinsteinRx AI with the PharmacyChain blockchain. The deal encompasses PharmacyChain expansion, medical drone deployment and the Health Lives Here app launch. A pending QOLPOM IP acquisition will integrate biometric confirmation technology ahead of the app's launch.
4. Strategic Growth Partnerships and Product Pipeline
The company’s joint venture with KareRx is expected to boost monthly pharmacy sales and expand manufacturer relationships. Tollo Health’s upcoming nutraceutical lineup—starting with Forzet and including Galectovid and Tollovid—will be integrated into the Health Lives Here platform alongside NFL Alumni collaborations.
